SEC Tracker
Get the app

ProMIS Neurosciences PMN

ProMIS Neurosciences Q1 FY26: net loss $8.2M; diluted EPS −$1.26

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers ProMIS Neurosciences reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$8.2MAgainst −$7.3M in Q1 FY2510-Q income statement, on EDGAR
  2. Diluted EPS−$1.26Against −$13,125.00 in Q1 FY2510-Q income statement, on EDGAR
  3. Cash and cash equivalents$63.8M+663% from $8.4M in Q1 FY25Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  4. Cash from operations−$12.4MAgainst −$4.9M in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when ProMIS Neurosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Cumberland Pharmaceuticals CPIX public float $29M, Jun 30, 2025
  2. Provectus Biopharmaceuticals PVCT public float $31M, Jun 30, 2025
  3. Rockwell Medical RMTI public float $29M, Jun 30, 2025
  4. Rein Therapeutics RNTX public float $32M, Jun 30, 2025
  5. Palatin Technologies PTN public float $26M, Dec 31, 2025